Melanoma
Clinical Insights
How aging affects melanoma development and treatment response
Conference Coverage
Real-world data support adjuvant immunotherapy for stage III melanoma
Immunotherapy after surgery for stage III melanoma conferred survival advantages in a real-world population.
News from the FDA/CDC
FDA approves new indications for pembrolizumab
Conference Coverage
Personalized cancer vaccine may enhance checkpoint inhibitor activity
Conference Coverage
Study evaluates number of needed to refer, biopsy for diagnosing a melanoma
“Even by being mindful of just the patient’s age, primary care providers can follow patients clinically with a tailored differential diagnosis in...
Conference Coverage
Vulvar melanoma is increasing in older women
Survival is markedly worse after age 60, when the nodular subtype prevails.
Conference Coverage
Combo exhibits activity in metastatic mucosal melanoma
The overall response rate was 48.5%.
Conference Coverage
Adding low-dose ipi to pembro seems safer, still effective for advanced melanoma
An ipilimumab dose of 1 mg/kg appears safer than a 3-mg/kg dose, when given in combination with pembrolizumab to patients with advanced melanoma...
Feature
Can an app guide cancer treatment decisions during the pandemic?
From the Journals
Biologics may carry melanoma risk for patients with immune-mediated inflammatory diseases
“We advocate for more large, well-designed studies of this issue to be performed to help improve certainty,” the researchers said.
Feature
‘A good and peaceful death’: Cancer hospice during the pandemic